Please assess the completion status of the following clinical trial:

Trial Title: Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women \> 18 years,~* Operated for a breast cancer by mastectomy with or without lymph node dissection, without immediate reconstruction,~* Capable of understanding the antalgic protocol,~* No contraindication to the local anesthesics,~* Social security affiliation,~* Signed informed consent.~Exclusion Criteria:~* Preoperative radiotherapy,~* Local infection,~* Contra-indication to the local anesthetic or to CCP,~* Contra-indication for the use of morphine,~* Contra-indication for the use of remifentanil,~* Addiction to opioid analgesics know or not,~* Allergy to local anesthetics,~* Hepatic or renal impairment grim known,~* Previous surgery on the operated breast,~* Pregnant women, or child-bearing potential, or lactating women,~* Patient deprived of liberty or under supervision of a guardian.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine (Type: EXPERIMENTAL): Ropivacaine
- placebo (Type: PLACEBO_COMPARATOR): physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).